Get 40% Off
🤯 This Tech Portfolio is up 29% YTD! Join Now to Get April’s Top PicksGet The Picks – Just 99 USD

Amazon Fear Grips Retail Pharmacy Space, Alliances Continue

Published 01/15/2019, 08:39 PM
Updated 07/09/2023, 06:31 AM

It seems that e-commerce giant Amazon's (NASDAQ:AMZN) entry in the pharmacy retail market along with other non-healthcare heavyweights like Berkshire Hathaway (NYSE:BRKa) and JPMorgan (NYSE:JPM) has initiated a new episode in the healthcare space. According to many market watchers, the traditional retail pharmacy and drugstore industry is set to undergo a sea change.

This development has been taken quite seriously by drugstore industry players who are unwilling to give up and lose their turf. These traditional pharmacy players are currently coming together to defend their position.

Consolidations in the Traditional Pharmaceutical and Drug Retail Space

After underperforming for a year, shares of Walgreens (NASDAQ:WBA) finally rallied 1.6% to close at $71.79 after the company entered into a seven-year alliance with Microsoft Corporation (NASDAQ:MSFT) .

The partnership will combine Microsoft Azure, Microsoft's cloud and AI platform, health care investments and new retail solutions, with Walgreen’s customer reach, convenient locations, outpatient health care services and industry expertise. According to a CNBC article, this alliance will explore digital health opportunities within stores and develop software for managing patient engagement.



While Amazon is trying to figure out ways to enter the multibillion dollar pharmacy industry, this is not the first attempt made by Walgreens to counter competition. Following Amazon’s foray into the healthcare retail industry last June (through the purchase of online pharmacy PillPack in December), Walgreens formed an alliance with Alphabet’s (NASDAQ:GOOGL) life sciences and healthcare segment, Verily, to collaborate on multiple projects. According to Walgreens, this strategic tie-up was designed to combine Verily’s healthcare technology innovation with Walgreens’ pharmacy services.

In this regard, we note that following Amazon’s PillPack deal, Walgreens CEO Stefano Pessina stated he was "not particularly worried" about Amazon. Walgreens currently carries a Zacks Rank #3 (Hold). You can see the complete list of today’s Zacks #1 Rank (Strong Buy) stocks here.

Another established player CVS Health (NYSE:CVS) is also following Walgreens’ footstep. This Zacks Rank #1 PBM (pharmacy benefit manager) company achieved a momentous healthcare consolidation by acquiring United States’ third largest health insurer Aetna (NYSE:AET) for a colossal sum of $70 billion.

Last month, prominent health insurer Cigna (NYSE:CI) merged with PBM player, Express Scripts (NASDAQ:ESRX). This latest deal can effectively drive the breadth of value-based relationships for Cigna and add to its fast-growing collaborative care network.

Summing Up

In any business, bankable human resource and strong financial position matter the most. And Amazon has both. Undoubtedly, Amazon’s entry has resulted in an upheaval in the prescription drug industry with major players struggling to keep afloat.

However, some analysts believe those preferring cash payments are expected to opt for Amazon’s pharmacy services. However, the percentage of this population is quite nominal. Moreover, patients with the need for immediate drugs will prefer buying them from stores over waiting for online delivery.

Considering these factors, major analysts believe there is enough scope left for the existing industry behemoths to maintain a competitive edge.

More Stock News: This Is Bigger than the iPhone!

It could become the mother of all technological revolutions. Apple (NASDAQ:AAPL) sold a mere 1 billion iPhones in 10 years but a new breakthrough is expected to generate more than 27 billion devices in just 3 years, creating a $1.7 trillion market.

Zacks has just released a Special Report that spotlights this fast-emerging phenomenon and 6 tickers for taking advantage of it. If you don't buy now, you may kick yourself in 2020.

Click here for the 6 trades >>



Original post

Zacks Investment Research

Latest comments

Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2024 - Fusion Media Limited. All Rights Reserved.